HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis.

AbstractOBJECTIVE:
To evaluate long term efficacy of three iterative courses of three weekly intra-articular (IA) injections of NRD101 in the treatment of symptomatic knee osteoarthritis (OA).
PATIENTS AND METHODS:
A 1 year prospective, multicentre, randomised, double blind, placebo controlled study of 301 patients aged >50 years with painful and radiological medial knee OA. Patients were randomly assigned into three groups receiving: (1) three courses of three IA injections of hyaluronic acid (HA) + oral placebo; (2) IA injections of saline solution + diacerein 100 mg/day; (3) IA injections of saline solution + oral placebo. Demographic data and symptomatic criteria-pain, Lequesne's index, patient's global assessment of disease activity, percentage of painful days-were obtained during the study; primary structural criterion was JSW. Efficacy criteria were changes in pain VAS, joint space narrowing (JSN), and percentage of progressors (JSN >0.5 mm). An intention to treat analysis was used for symptomatic variables, and completer analysis for structural variables.
RESULTS:
Baseline characteristics were similar between the three groups. Mean (SD) improvement in pain VAS was clinically relevant (-33.9 (27.3), n = 301), but with no difference between the groups (p = 0.96). JSW deteriorated (-0.09 (0.55) mm, n = 277, p = 0.01), but with no difference between the groups (p = 0.82). Percentages of progressors were 17.7, 18.9, and 20.3% (p = 0.90), in groups 1, 2, and 3, respectively.
CONCLUSION:
A weak but statistically significant structural deterioration occurred over 1 year, together with clinically relevant symptomatic improvement in patients receiving oral drug and iterative IA injections. Symptomatic and/or structural effects for both this new HA compound and diacerein were not demonstrated.
AuthorsT Pham, A Le Henanff, Ph Ravaud, P Dieppe, L Paolozzi, M Dougados
JournalAnnals of the rheumatic diseases (Ann Rheum Dis) Vol. 63 Issue 12 Pg. 1611-7 (Dec 2004) ISSN: 0003-4967 [Print] England
PMID15331394 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Anthraquinones
  • Anti-Inflammatory Agents, Non-Steroidal
  • NRD101
  • diacerein
  • Hyaluronic Acid
Topics
  • Aged
  • Anthraquinones (adverse effects, therapeutic use)
  • Anti-Inflammatory Agents, Non-Steroidal (adverse effects, therapeutic use)
  • Disease Progression
  • Double-Blind Method
  • Female
  • Humans
  • Hyaluronic Acid (adverse effects, analogs & derivatives, therapeutic use)
  • Injections, Intra-Articular
  • Male
  • Middle Aged
  • Osteoarthritis, Knee (drug therapy)
  • Pain Measurement
  • Prospective Studies
  • Severity of Illness Index
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: